Codi QR

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study

Introduction: SCLC is characterized by aggressiveness and limited treatment options, especially in extensive-stage SCLC (ES-SCLC). Immunotherapy added to the platinum-etoposide combination has recently become standard in this setting. This retrospective study aims to evaluate the real-world effectiv...

Descripció completa

Guardat en:
Autors principals: Laura Moliner, MD, Núria Zellweger, MSc, Sabine Schmid, MD, Martina Bertschinger, MD, Christine Waibel, MD, Ferdinando Cerciello, MD, PhD, Patrizia Froesch, MD, Michael Mark, MD, Adrienne Bettini, MD, Pirmin Häuptle, MD, Veronika Blum, MD, Lisa Holer, MSc, Stefanie Hayoz, PhD, Martin Früh, MD, Samreen Ahmed, FRCP, MD, MBBS, MSc, Shradha Bhagani, MD, Nicola Steele, MD, Hannah-Leigh Gray, BSc, Stephen D. Robinson, MD, Michael Davidson, MD (Res), Samantha Cox, MD, MSc, MBBCh, Taha Khalid, MD, Tom R. Geldart, MD, Luke Nolan, FRCS, PhD, Deborah C. Scott, MBChB (MRCP), Lindsay Hennah, MD, Tom Newsom-Davis, MD, PhD, Emma Rathbone, MD, PhD, Catherine Handforth, MD, Arshi Denton, MD, Shairoz Merchant, PhD, Fiona Blackhall, MD, PhD, Laetitia A. Mauti, MD, Raffaele Califano, MD, Sacha I. Rothschild, MD, PhD
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2025-01-01
Col·lecció:JTO Clinical and Research Reports
Matèries:
SCLC
Real-world data
Immunotherapy
Special populations
Accés en línia:http://www.sciencedirect.com/science/article/pii/S2666364324001140
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars